Oculis Holding AG (OCS) Retained Earnings (2021 - 2026)
Quarterly Retained Earnings fell 48.88% to -$527.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$527.9 million through Mar 2026, down 48.88% year-over-year, with the annual reading at -$481.1 million for FY2025, 47.59% down from the prior year.
Oculis Holding AG's Retained Earnings history spans 6 years, with the latest figure at -$527.9 million for Q1 2026.
- Retained Earnings came in at -$527.9 million for Q1 2026, down from -$481.1 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$115.2 million in Q4 2022 to a low of -$527.9 million in Q1 2026.
- The 5-year median for Retained Earnings is -$296.5 million (2024), against an average of -$315.6 million.
- Year-over-year, Retained Earnings crashed 95.51% in 2023 and then crashed 38.55% in 2024.
- Oculis Holding AG's Retained Earnings stood at -$115.2 million in 2022, then tumbled by 95.51% to -$225.2 million in 2023, then plummeted by 44.73% to -$326.0 million in 2024, then plummeted by 47.59% to -$481.1 million in 2025, then decreased by 9.72% to -$527.9 million in 2026.
- Per Business Quant, the three most recent readings for OCS's Retained Earnings are -$527.9 million (Q1 2026), -$481.1 million (Q4 2025), and -$451.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 36.42 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | 130.89 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Oculis Holding AG | 24.51 Bn | 24.21 Bn | - | -527.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -527.87 Mn |
| Dec 31, 2025 | -481.09 Mn |
| Sep 30, 2025 | -451.29 Mn |
| Jun 30, 2025 | -415.69 Mn |
| Mar 31, 2025 | -354.55 Mn |
| Dec 31, 2024 | -325.97 Mn |
| Sep 30, 2024 | -296.52 Mn |
| Jun 30, 2024 | -261.75 Mn |
| Mar 31, 2024 | -247.32 Mn |
| Dec 31, 2023 | -225.22 Mn |
| Sep 30, 2023 | -212.03 Mn |
| Jun 30, 2023 | -188.93 Mn |
| Dec 31, 2022 | -115.20 Mn |
| Dec 31, 2021 | -78.39 Mn |